Table 6.
Incidence of late radiation toxicity in prostate cancer
| Institutes | Treatment | Dose/fractions | No. of patients | Late ≥G2 injury |
|
|---|---|---|---|---|---|
| Rectal | Urinary | ||||
| Christie H. (80) | IMRT | 60 Gy/20 fr | 60 | 9.5% | 4.0% |
| Princess Margaret H. (81) | IMRT | 60 Gy/20 fr | 92 | 6.3% | 10.0% |
| Cleveland CF. (82) | IMRT | 70 Gy/28 fr | 770 | 4.4% | 5.2% |
| Stanford U. (83) | SRT | 36.25 Gy/5 fr | 41 | 15.0% | 29.0% |
| RTOG 9406 (84) | 3DCRT | 68.4–79.2 Gy/38–41 fr | 275 | 7–16% | 18–29% |
| 3DCRT | 78.0 Gy/39 fr | 118 | 25–26% | 23–28% | |
| Loma Linda U. (85) | Proton | 75.0 GyE/39 fr | 901 | 3.5% | 5.4% |
| NIRS (88,89) | Carbon | 63.0 GyE/20 fr | 216 | 2.3% | 6.1% |
| Carbon | 57.6 GyE/16 fr | 539 | 0.6% | 1.9% | |
IMRT, intensity-modulated radiotherapy; 3DCRT, three-dimensional conformal radiotherapy; SRT, stereotactic radiotherapy.